Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: In the phase III SPARC trial, satraplatin, an oral platinum analogue, demonstrated anticancer activity in men with metastatic castration-resistant prostate cancer (mCRPC). Repeat biopsies are uncommon in mCRPC, limiting the feasibility of tissue–based biomarkers. This phase II study soug...

Descripción completa

Detalles Bibliográficos
Autores principales: Liaw, Bobby C, Tsao, Che-Kai, Seng, Sonia, Jun, Tomi, Gong, Yixuan, Galsky, Matthew D, Oh, William K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078918/
https://www.ncbi.nlm.nih.gov/pubmed/36519763
http://dx.doi.org/10.1093/oncolo/oyac224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078918/
https://www.ncbi.nlm.nih.gov/pubmed/36519763
http://dx.doi.org/10.1093/oncolo/oyac224

Ejemplares similares